NCT01078571 arm group 03d6f4bd602bf161d0b7065a46bceca2 [clinicaltrials_resource:NCT01078571/arm-group/03d6f4bd602bf161d0b7065a46bceca2]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01078571 arm group 03d6f4bd602bf161d0b7065a46bceca2 [clinicaltrials_resource:NCT01078571/arm-group/03d6f4bd602bf161d0b7065a46bceca2]
Bio2RDF identifier
NCT01078571/arm-group/03d6f4bd602bf161d0b7065a46bceca2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... d6f4bd602bf161d0b7065a46bceca2
description [clinicaltrials_vocabulary:description]
RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
identifier
clinicaltrials_resource:NCT01078571/arm-group/03d6f4bd602bf161d0b7065a46bceca2
title
NCT01078571 arm group 03d6f4bd602bf161d0b7065a46bceca2
@en
type
label
NCT01078571 arm group 03d6f4bd ...... 6f4bd602bf161d0b7065a46bceca2]
@en